New approach to treating diabetic eye disease

New approach to treating diabetic eye disease
http://www.yahoo.corn/kalvista-pharrnaceuticals-jdrf-forrn-research-pai1nership-focusedon-
novel-approach-for-treating-diabetic-eye-disease.html
The Juvenile Diabetes Research Foundation (JDRF) and KalVista
Pharmaceuticals have formed a research partnership focused on
developing a new approach to treating diabetic eye disease.
Eye disease is the most common complication of type 1 diabetes ranging
from mild retinopathy to proliferative retinopathy with macular edema.
Treatment to prevent or reverse macular edema is a major unmet clinical
need which is why the JDRF is providing up to $2.2 million to KalVista.
KalVista is focusing on plasma kallikrein inhibitors to decreae
retinal vessel leakage. Kallikrein increases blood vessel leakage and
thickening of the retina. A kallikrein inhibitor that will be injected into the
vitreous or administered orally will be developed and tested for safety
and efficacy by KalVista.
An oral medication would be preferred. Getting a shot in your eye
would be horrible.